ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Press Release
HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)
Jun 21, 2024 18:30 JST
HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the American Diabetes Association's (ADA) 84th Scientific Sessions, taking place from June 21-24, 2024 in Orlando, Florida.
More info..
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
Jun 05, 2024 09:00 JST
HighTide Therapeutics, Inc. (HKEX: 2511), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced that it will make multiple presentations at the European Association for the Study of the Liver (EASL) Congress, taking place from June 5-8, 2024 in Milan, Italy.
More info..
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)
Jan 11, 2023 21:00 JST
HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH").
More info..
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
Jan 05, 2023 18:00 JST
HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases
More info..
AJG Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis
Nov 17, 2022 08:00 JST
HighTide Therapeutics, Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the publication of the results of their Phase 2 study of HTD1801 in adults with primary sclerosing cholangitis (PSC) in the American Journal of Gastroenterology.
More info..
American Journal of Gastroenterology Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis
Nov 16, 2022 23:00 JST
HighTide Therapeutics, Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced publication of the results of their Phase 2 study of HTD1801 in adults with primary sclerosing cholangitis (PSC) in the American Journal of Gastroenterology.
More info..
1
Latest Release
Mitsubishi Corporation, KDDI CORPORATION, Lawson, Inc. Launching an Initiative to Transform into "Next-generation Convenience Store"
Sep 20, 2024 18:02 JST
Hitachi Rail is innovating and delivering transformative 5G digital signalling
Sep 20, 2024 16:47 JST
Olympus Launches New 4K Camera Head for Urological Endoscopy
Sep 20, 2024 15:00 JST
Honda to Relocate the Base of its Rugby Team Activities
Sep 19, 2024 15:05 JST
Renewal of Compact CO2 Capture System "CO2MPACT(TM)" Series
Sep 19, 2024 14:35 JST
The world's first commercial copper die-cast rotor for railway traction motors
Sep 19, 2024 13:57 JST
NEC Secures Fifth Consecutive Worldwide Partner of the Year Award from Juniper Networks
Sep 19, 2024 13:08 JST
Fujitsu and Stellar Science Foundation form partnership agreement to foster innovation by supporting young researchers
Sep 19, 2024 10:31 JST
Approval in Principle (AiP) Acquired from Two Classification Societies for Low-Pressure Type Liquefied CO2 Carriers undergoing Pursuit of Standardization toward Realization of Large-Scale International Transportation from 2028 onwards
Sep 18, 2024 18:02 JST
Europe's First Post-Combustion Carbon Capture Plant Starts Operation with MHI Technology as part of the Ravenna CCS Project, Phase 1
Sep 18, 2024 17:24 JST
Eutelsat and Mitsubishi Heavy Industries Reach Agreement for Multiple Launches
Sep 18, 2024 17:19 JST
NEC Orchestrating Future Fund invests in Sakana AI to promote development of generative AI
Sep 18, 2024 13:02 JST
IHI, Fujitsu, and Mizuho Bank form agreement to launch joint business venture to provide total support scheme for J-Credit
Sep 18, 2024 11:28 JST
JCB and Azer Turk Bank launch JCB merchant acquiring operations across the Republic of Azerbaijan
Sep 17, 2024 17:00 JST
Fuji frustration for TOYOTA GAZOO Racing
Sep 17, 2024 15:01 JST
Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner
Sep 17, 2024 14:30 JST
Japan International Aerospace Exhibition 2024: Japan's largest comprehensive aerospace industry exhibition
Sep 17, 2024 12:00 JST
LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
Sep 17, 2024 10:08 JST
DENSO Wins Medals at 47th WorldSkills Competition
Sep 16, 2024 19:54 JST
Mitsubishi Corporation and ExxonMobil sign Project Framework Agreement to advance world's largest low-carbon hydrogen project
Sep 13, 2024 20:07 JST
More Latest Release >>